http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#Head http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#assertion http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#provenance http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#pubinfo http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#assertion http://purl.obolibrary.org/obo/DOID_14332 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_14332 http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00915 http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association http://www.w3.org/2000/01/rdf-schema#label amantadine hydrochloride capsules usp are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus amantadine hydrochloride capsules usp are also indicated in the treatment of parkinsonism and drug induced extrapyramidal reactions influenza a prophylaxis amantadine hydrochloride capsules usp are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection because amantadine hydrochloride does not completely prevent the host immune response to influenza a infection individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses following vaccination during an influenza a outbreak amantadine hydrochloride capsules usp prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response influenza a treatment amantadine hydrochloride capsules usp are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza a virus strains especially when administered early in the course of illness there are no well controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules usp will avoid the development of influenza a virus pneumonitis or other complications in high risk patients there is no clinical evidence indicating that amantadine hydrochloride capsules usp are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza a virus strains the following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules usp amantadine hydrochloride capsules usp is not a substitute for early vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices influenza viruses change over time emergence of resistance mutations could decrease drug effectiveness other factors for example changes in viral virulence might also diminish clinical benefit of antiviral drugs prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules usp parkinson s disease syndrome amantadine hydrochloride capsules usp are indicated in the treatment of idiopathic parkinson s disease paralysis agitans postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication it is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis in the treatment of parkinson s disease amantadine hydrochloride capsules usp are less effective than levodopa 3 3 4 dihydroxyphenyl l alanine and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established drug induced extrapyramidal reactions amantadine hydrochloride capsules usp are indicated in the treatment of drug induced extrapyramidal reactions although anticholinergic type side effects have been noted with amantadine hydrochloride capsules usp when used in patients with drug induced extrapyramidal reactions there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00915 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#provenance http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#pubinfo http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#sig http://purl.org/nanopub/x/hasSignature YXqetJJHFIc3Qz4mGng51yuErSYyJisI5zkzRjtLzXt2jpvMa4mf7KUjNj+uAAJ9hMsG0dpcND5KD4Rf2rtc/uPlhlMkgQh4MNgkDHL4nZepuSh4gZqBGrgm1MUwXED9fWFxhnJ8+jxtX5fbO/DHuvkJvCliKy8gdMnaU6tr504= http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q http://purl.org/dc/terms/created 2021-06-21T09:58:16.891+02:00 http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAgGrcr00vorpimZQljloBkjSs1ljwZaSNgfDBmXfY30Q https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs